Literature DB >> 16322069

Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation.

Yoshiko Fujita1, Masanori Yoshizumi, Yuki Izawa, Nermin Ali, Hideki Ohnishi, Yasuhisa Kanematsu, Keisuke Ishizawa, Koichiro Tsuchiya, Toshiaki Tamaki.   

Abstract

Lysophosphatidylcholine (LPC), a major lipid component of oxidized low-density lipoprotein, is a bioactive lipid molecule involved in numerous biological processes including the progression of atherosclerosis. Recently orphan G protein-coupled receptors were identified as high-affinity receptors for LPC. Although several G protein-coupled receptor ligands transactivate receptor tyrosine kinases, LPC-stimulated transactivation of receptor tyrosine kinase has not yet been reported. Here we observed for the first time that LPC treatment of human umbilical vein endothelial cells (HUVECs) induces tyrosyl phosphorylation of vascular endothelial growth factor receptor 2 [fetal liver kinase-1/kinase-insert domain-containing receptor, Flk-1/KDR)]. Flk-1/KDR transactivation by LPC was inhibited by vascular endothelial growth factor receptor tyrosine kinase inhibitors, SU1498 and 4-[(4'-chloro-2'-fluoro) phenylamino]6,7-dimethoxyquinazoline (VTKi) in immunoprecipitation. Furthermore, we examined the effects of the Src family kinases inhibitors, herbimycin A and 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine (PP2), on LPC-induced Flk-1/KDR transactivation. Results from Western blots, c-Src is involved in LPC-induced Flk-1/KDR transactivation because herbimycin A and PP2 inhibited this transactivation. Kinase-inactive (KI) Src transfection also inhibited LPC-induced Flk-1/KDR transactivation. In addition, results from Western blots, ERK1/2 and Akt, which are downstream effectors of Flk-1/KDR, were also activated by LPC, and this was inhibited by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in HUVECs. LPC-induced stimulation of HUVEC proliferation was shown to be secondary to transactivation because it was suppressed by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in dimethylthiazoldiphenyltetra-zoliumbromide assay. These findings suggest that LPC-induced Flk-1/KDR transactivation via c-Src may have important implications for the progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322069     DOI: 10.1210/en.2005-0644

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Enhanced endothelialization on surface modified poly(L-lactic acid) substrates.

Authors:  Hao Xu; Rajendrasing Deshmukh; Richard Timmons; Kytai Truong Nguyen
Journal:  Tissue Eng Part A       Date:  2010-12-18       Impact factor: 3.845

2.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

Review 3.  Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.

Authors:  Jeffrey M Craft; Dennis Hallahan
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

4.  Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators.

Authors:  Fanny Surrel; Ikram Jemel; Eric Boilard; James G Bollinger; Christine Payré; Carine M Mounier; Kati A Talvinen; Veli J O Laine; Timo J Nevalainen; Michael H Gelb; Gérard Lambeau
Journal:  Mol Pharmacol       Date:  2009-07-14       Impact factor: 4.436

5.  Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability.

Authors:  Melissa L Petreaca; Min Yao; Yan Liu; Kathryn Defea; Manuela Martins-Green
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

6.  Cytosolic phospholipase A2: targeting cancer through the tumor vasculature.

Authors:  Amanda Linkous; Ling Geng; Andrej Lyshchik; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

7.  Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis.

Authors:  Amanda G Linkous; Eugenia M Yazlovitskaya; Dennis E Hallahan
Journal:  J Natl Cancer Inst       Date:  2010-08-20       Impact factor: 13.506

8.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.

Authors:  Paul Canning; Bridget-Ann Kenny; Vivien Prise; Josephine Glenn; Mosharraf H Sarker; Natalie Hudson; Martin Brandt; Francisco J Lopez; David Gale; Philip J Luthert; Peter Adamson; Patric Turowski; Alan W Stitt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-13       Impact factor: 11.205

9.  Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.

Authors:  Dinesh Thotala; Jeffrey M Craft; Daniel J Ferraro; Rama P Kotipatruni; Sandeep R Bhave; Jerry J Jaboin; Dennis E Hallahan
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.

Authors:  Eugene Kim; Hanna Maja Tunset; Jana Cebulla; Riyas Vettukattil; Heidi Helgesen; Astrid Jullumstrø Feuerherm; Olav Engebråten; Gunhild Mari Mælandsmo; Berit Johansen; Siver Andreas Moestue
Journal:  BMC Cancer       Date:  2016-03-07       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.